内分泌治疗对老年癌症患者脂质代谢及营养状况的影响

Q4 Medicine

中华泌尿外科杂志 Pub Date : 2020-02-15 DOI:10.3760/CMA.J.ISSN.1000-6702.2020.02.009

Zijian Tian, H. Hou, S. Lai, Shengjie Liu, Xingbo Long, Miao Wang, Jianye Wang, Ming Liu

{"title":"内分泌治疗对老年癌症患者脂质代谢及营养状况的影响","authors":"Zijian Tian, H. Hou, S. Lai, Shengjie Liu, Xingbo Long, Miao Wang, Jianye Wang, Ming Liu","doi":"10.3760/CMA.J.ISSN.1000-6702.2020.02.009","DOIUrl":null,"url":null,"abstract":"Objective \nTo analyze effects of androgen deprivation therapy on lipid metabolism and nutritional status in patients with prostate cancer. \n \n \nMethods \nThe clinical data of 255 elderly patients (≥ 65 years old) with prostate cancer who received endocrine therapy and complete follow-up data from January 2010 to December 2018 were analyzed retrospectively. The median age of the 255 patients was 76 years(65-92). The average PSA of patients was (58.15±9.62) ng/ml, where 101 patients had PSA 20 ng/ml. All patients were diagnosed pathologically by prostate biopsy. As for Gleason score, Gleason score≤6, Gleason score=7 and Gleason score≥ 8 had 62, 103 and 90 patients, respectively. Endocrine therapy included maximum androgen blockade (197 cases) and drug castration (58 cases), and continued for at least 1 year. Among them, 123 cases had complete blood lipid index data, and the subgroup analysis was based on the age of 80 years old, including 98 cases aged 65 to 80 years old and 25 cases over 80 years old. A total of 186 cases had complete data of total protein and albumin, of which 147 cases were 65 years old and 80 years old and 39 cases were more than 80 years old. Before treatment, cholesterol was (4.08±0.87)mmol/L, including (4.14±0.86) mmol/L in the 65-80 years old group, (3.82±0.88) mmol/L in >80 years old group; triglyceride was (1.23 ±0.56) mmol/L, 65-80 age group was (1.26±0.56) mmol/L and >80 years old group was (1.11±0.57) mmol/L; High density lipoprotein cholesterol was(1.09±0.24)mmol/L, 65-80 age group was (1.10±0.25) mmol/L and >80 years group was (1.04±0.21) mmol/L. Low density lipoprotein cholesterol was (2.50±0.78)mmol/L, 65~80 age group was (2.55±0.77)mmol/L and (2.34±0.83) mmol/L in >80 years old group.The total protein before endocrine therapy was (63.81±5.93) g/L, including (63.95±5.79) g/L in the 65-80 years old group, (63.30±6.49) g/L in >80 years old group. In terms of pre-treatment albumin (39.68±3.50) g/L, including (39.82±3.60) g/L in the 65-80 years old group and (39.21±3.12) g/L in >80 years old group. The differences of various indexes before and after treatment were analyzed. \n \n \nResults \nThe results of blood lipid data analysis of 123 cases showed that, there were increased significant differences(P 0.05). The results of data analysis of 186 cases of total protein and albumin showed that, the total protein after treatment was (62.81±7.34) g/L, which was not significantly different from that before treatment (P>0.05). The total protein in 65-80 years old group after treatment was (62.36±7.36) g/L, which decrease and have statistical significantly different from that before treatment (P 80 years old group after treatment was (64.49±7.12) g/L, it was higher than that before treatment, but the difference was not statistically significant (P>0.05). The level of albumin after endocrine therapy was (38.34±4.48) g/L, which was significantly different from that before treatment (P 80 years old group after treatment were (38.32±4.54) g/L and (38.44±4.30) g/L respectively, but only in the group of 65 to 80 years old, there were significant differences compared with those before treatment (P<0.05). \n \n \nConclusion \nEndocrine therapy can not only significantly increase total cholesterol, triglyceride, low density lipoprotein cholesterol and high density lipoprotein cholesterol in elderly patients with prostate cancer, but also significantly reduce albumin after treatment. \n \n \nKey words: \nProstate cancer; Endocrine therapy; Lipid metabolism; Nutritional status","PeriodicalId":10343,"journal":{"name":"中华泌尿外科杂志","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effects of endocrine therapy on lipid metabolism and nutritional status in elderly patients with prostate cancer\",\"authors\":\"Zijian Tian, H. Hou, S. Lai, Shengjie Liu, Xingbo Long, Miao Wang, Jianye Wang, Ming Liu\",\"doi\":\"10.3760/CMA.J.ISSN.1000-6702.2020.02.009\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective \\nTo analyze effects of androgen deprivation therapy on lipid metabolism and nutritional status in patients with prostate cancer. \\n \\n \\nMethods \\nThe clinical data of 255 elderly patients (≥ 65 years old) with prostate cancer who received endocrine therapy and complete follow-up data from January 2010 to December 2018 were analyzed retrospectively. The median age of the 255 patients was 76 years(65-92). The average PSA of patients was (58.15±9.62) ng/ml, where 101 patients had PSA 20 ng/ml. All patients were diagnosed pathologically by prostate biopsy. As for Gleason score, Gleason score≤6, Gleason score=7 and Gleason score≥ 8 had 62, 103 and 90 patients, respectively. Endocrine therapy included maximum androgen blockade (197 cases) and drug castration (58 cases), and continued for at least 1 year. Among them, 123 cases had complete blood lipid index data, and the subgroup analysis was based on the age of 80 years old, including 98 cases aged 65 to 80 years old and 25 cases over 80 years old. A total of 186 cases had complete data of total protein and albumin, of which 147 cases were 65 years old and 80 years old and 39 cases were more than 80 years old. Before treatment, cholesterol was (4.08±0.87)mmol/L, including (4.14±0.86) mmol/L in the 65-80 years old group, (3.82±0.88) mmol/L in >80 years old group; triglyceride was (1.23 ±0.56) mmol/L, 65-80 age group was (1.26±0.56) mmol/L and >80 years old group was (1.11±0.57) mmol/L; High density lipoprotein cholesterol was(1.09±0.24)mmol/L, 65-80 age group was (1.10±0.25) mmol/L and >80 years group was (1.04±0.21) mmol/L. Low density lipoprotein cholesterol was (2.50±0.78)mmol/L, 65~80 age group was (2.55±0.77)mmol/L and (2.34±0.83) mmol/L in >80 years old group.The total protein before endocrine therapy was (63.81±5.93) g/L, including (63.95±5.79) g/L in the 65-80 years old group, (63.30±6.49) g/L in >80 years old group. In terms of pre-treatment albumin (39.68±3.50) g/L, including (39.82±3.60) g/L in the 65-80 years old group and (39.21±3.12) g/L in >80 years old group. The differences of various indexes before and after treatment were analyzed. \\n \\n \\nResults \\nThe results of blood lipid data analysis of 123 cases showed that, there were increased significant differences(P 0.05). The results of data analysis of 186 cases of total protein and albumin showed that, the total protein after treatment was (62.81±7.34) g/L, which was not significantly different from that before treatment (P>0.05). The total protein in 65-80 years old group after treatment was (62.36±7.36) g/L, which decrease and have statistical significantly different from that before treatment (P 80 years old group after treatment was (64.49±7.12) g/L, it was higher than that before treatment, but the difference was not statistically significant (P>0.05). The level of albumin after endocrine therapy was (38.34±4.48) g/L, which was significantly different from that before treatment (P 80 years old group after treatment were (38.32±4.54) g/L and (38.44±4.30) g/L respectively, but only in the group of 65 to 80 years old, there were significant differences compared with those before treatment (P<0.05). \\n \\n \\nConclusion \\nEndocrine therapy can not only significantly increase total cholesterol, triglyceride, low density lipoprotein cholesterol and high density lipoprotein cholesterol in elderly patients with prostate cancer, but also significantly reduce albumin after treatment. \\n \\n \\nKey words: \\nProstate cancer; Endocrine therapy; Lipid metabolism; Nutritional status\",\"PeriodicalId\":10343,\"journal\":{\"name\":\"中华泌尿外科杂志\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-02-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中华泌尿外科杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/CMA.J.ISSN.1000-6702.2020.02.009\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华泌尿外科杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1000-6702.2020.02.009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

目的分析雄激素剥夺治疗对前列腺癌症患者脂代谢及营养状况的影响。方法回顾性分析2010年1月至2018年12月255例老年（≥65岁）癌症前列腺癌患者接受内分泌治疗的临床资料和完整的随访资料。255名患者的中位年龄为76岁（65-92岁）。患者的平均PSA为（58.15±9.62）ng/ml，其中101例患者的PSA为20 ng/ml。所有患者均经前列腺活检病理诊断。在Gleason评分方面，Gleason分≤6、Gleason得分=7和Gleason分数≥8的患者分别为62例、103例和90例。内分泌治疗包括最大雄激素阻断（197例）和药物阉割（58例），并持续至少1年。其中，123例血脂指标数据完整，亚组分析以80岁为年龄段，其中65～80岁98例，80岁以上25例。186例患者的总蛋白和白蛋白数据完整，其中147例为65岁和80岁，39例为80岁以上。治疗前胆固醇为（4.08±0.87）mmol/L，其中65-80岁组胆固醇为（4.14±0.86）mmol/L；>80岁组为（3.82±0.88）mmol/L；甘油三酯为（1.23±0.56）mmol/L，65-80岁组为（1.26±0.56”mmol/L，80岁以上组为（1.11±0.57）mmol/L；高密度脂蛋白胆固醇为（1.09±0.24）mmol/L，65-80岁年龄组为（1.10±0.25）mmol/L；>80岁组为（1.04±0.21）mmol/L。低密度脂蛋白胆固醇为（2.50±0.78）mmol/L，65～80岁组为（2.55±0.77）mmol/L；80岁以上组为（2.34±0.83）mmol/L。内分泌治疗前总蛋白为（63.81±5.93）g/L，其中65-80岁组为（63.95±5.79）g/L，>80岁组（63.30±6.49）g/L。治疗前白蛋白（39.68±3.50）g/L，其中65-80岁组为（39.82±3.60）g/L；>80岁组则为（39.21±3.12）g/L。分析治疗前后各项指标的差异。结果对123例患者的血脂数据分析结果显示，有显著性差异（P＜0.05），对186例患者的总蛋白和白蛋白数据分析结果表明：治疗后总蛋白为（62.81±7.34）g/L，65-80岁组治疗后总蛋白为（62.36±7.36）g/L，与治疗前相比有统计学意义（P＜0.05），内分泌治疗后白蛋白水平为（38.34±4.48）g/L，与治疗前有显著性差异（P 80岁组治疗后分别为（38.32±4.54）g/L和（38.44±4.30）g/L，仅65～80岁组，结论内分泌治疗不仅能显著提高老年前列腺癌症患者的总胆固醇、甘油三酯、低密度脂蛋白胆固醇和高密度脂蛋白蛋白胆固醇，而且能显著降低治疗后的白蛋白。关键词：前列腺癌症；内分泌治疗；脂质代谢；营养状况

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Effects of endocrine therapy on lipid metabolism and nutritional status in elderly patients with prostate cancer

Objective To analyze effects of androgen deprivation therapy on lipid metabolism and nutritional status in patients with prostate cancer. Methods The clinical data of 255 elderly patients (≥ 65 years old) with prostate cancer who received endocrine therapy and complete follow-up data from January 2010 to December 2018 were analyzed retrospectively. The median age of the 255 patients was 76 years(65-92). The average PSA of patients was (58.15±9.62) ng/ml, where 101 patients had PSA 20 ng/ml. All patients were diagnosed pathologically by prostate biopsy. As for Gleason score, Gleason score≤6, Gleason score=7 and Gleason score≥ 8 had 62, 103 and 90 patients, respectively. Endocrine therapy included maximum androgen blockade (197 cases) and drug castration (58 cases), and continued for at least 1 year. Among them, 123 cases had complete blood lipid index data, and the subgroup analysis was based on the age of 80 years old, including 98 cases aged 65 to 80 years old and 25 cases over 80 years old. A total of 186 cases had complete data of total protein and albumin, of which 147 cases were 65 years old and 80 years old and 39 cases were more than 80 years old. Before treatment, cholesterol was (4.08±0.87)mmol/L, including (4.14±0.86) mmol/L in the 65-80 years old group, (3.82±0.88) mmol/L in >80 years old group; triglyceride was (1.23 ±0.56) mmol/L, 65-80 age group was (1.26±0.56) mmol/L and >80 years old group was (1.11±0.57) mmol/L; High density lipoprotein cholesterol was(1.09±0.24)mmol/L, 65-80 age group was (1.10±0.25) mmol/L and >80 years group was (1.04±0.21) mmol/L. Low density lipoprotein cholesterol was (2.50±0.78)mmol/L, 65~80 age group was (2.55±0.77)mmol/L and (2.34±0.83) mmol/L in >80 years old group.The total protein before endocrine therapy was (63.81±5.93) g/L, including (63.95±5.79) g/L in the 65-80 years old group, (63.30±6.49) g/L in >80 years old group. In terms of pre-treatment albumin (39.68±3.50) g/L, including (39.82±3.60) g/L in the 65-80 years old group and (39.21±3.12) g/L in >80 years old group. The differences of various indexes before and after treatment were analyzed. Results The results of blood lipid data analysis of 123 cases showed that, there were increased significant differences(P 0.05). The results of data analysis of 186 cases of total protein and albumin showed that, the total protein after treatment was (62.81±7.34) g/L, which was not significantly different from that before treatment (P>0.05). The total protein in 65-80 years old group after treatment was (62.36±7.36) g/L, which decrease and have statistical significantly different from that before treatment (P 80 years old group after treatment was (64.49±7.12) g/L, it was higher than that before treatment, but the difference was not statistically significant (P>0.05). The level of albumin after endocrine therapy was (38.34±4.48) g/L, which was significantly different from that before treatment (P 80 years old group after treatment were (38.32±4.54) g/L and (38.44±4.30) g/L respectively, but only in the group of 65 to 80 years old, there were significant differences compared with those before treatment (P<0.05). Conclusion Endocrine therapy can not only significantly increase total cholesterol, triglyceride, low density lipoprotein cholesterol and high density lipoprotein cholesterol in elderly patients with prostate cancer, but also significantly reduce albumin after treatment. Key words: Prostate cancer; Endocrine therapy; Lipid metabolism; Nutritional status

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

中华泌尿外科杂志 Medicine-Nephrology

CiteScore

0.10

自引率

0.00%

发文量

14180

期刊介绍： Chinese Journal of Urology (monthly) was founded in 1980. It is a publicly issued academic journal supervised by the China Association for Science and Technology and sponsored by the Chinese Medical Association. It mainly publishes original research papers, reviews and comments in this field. This journal mainly reports on the latest scientific research results and clinical diagnosis and treatment experience in the professional field of urology at home and abroad, as well as basic theoretical research results closely related to clinical practice. The journal has columns such as treatises, abstracts of treatises, experimental studies, case reports, experience exchanges, reviews, reviews, lectures, etc. Chinese Journal of Urology has been included in well-known databases such as Peking University Journal (Chinese Journal of Humanities and Social Sciences), CSCD Chinese Science Citation Database Source Journal (including extended version), and also included in American Chemical Abstracts (CA). The journal has been rated as a quality journal by the Association for Science and Technology and as an excellent journal by the Chinese Medical Association.